Navigation Links
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
Date:8/3/2009

FREMONT, Calif., Aug. 3 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC's Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in Boston, MA as part of IBC's Drug Discovery Week. Dr. Thompson has been appointed a member of the conference's scientific advisory board and will deliver the Conference Chair Opening Remarks. In addition, he will give a presentation and participate as a panel moderator.

Dr. Thompson's presentation, titled, "Design and Development of Synthetic siRNAs for Clinical Applications," will describe Quark's pipeline, which includes PF-04523655, a synthetic siRNA in Phase II clinical studies licensed by Pfizer in multiple ophthalmology indications, and QPI-1002, a synthetic siRNA in Phase I/II studies for two renal indications. The presentation will incorporate an update on Quark's clinical studies; a case study on the first siRNA administered systemically to man; and an overview of Quark's strategies to optimize synthetic siRNAs for clinical applications while avoiding off-target effects.

The Industry Leadership Forum panel Dr. Thompson will moderate is titled, "RNA Therapeutics - Are We Leveraging on the Promise?" It will cover the current state of development of siRNA, miRNA, antisense and aptamar therapeutics and examine how companies are capitalizing on the promise of the field. Panelists will include Paul Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.; Klaus Giese, Ph.D., Chief Scientific Officer, Vice President, Research, Silence Therapeutics AG; and Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation.

<
'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
2. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
7. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
8. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
9. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
10. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
11. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... provides important insights on the use of ... practice -, AMSTERDAM, The Netherlands, Dec. 14 ... prognosis test was,successfully implemented in the diagnostic process ... Netherlands. MammaPrint(R) assigned,up to one- third of the ...
... UC Riversides Douglas Ethell , an assistant ... die in disorders such as Alzheimers and Parkinsons, has ... Institute for Regenerative Medicine ( CIRM ), Californias stem ... Faculty Award by CIRM, will fund Ethells research on ...
... to traffic pollution may increase respiratory problems and reduce ... who studied the effects of road and traffic density ... border town of Ciudad Juarez in Mexico. , Our ... either at home or at school, can lead to ...
... Dec. 13 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... of two skilled,nursing facilities in California and one ... price of approximately $12.8 million., (Logo: ...
... practices can put as much strain on a womans ... year, an extensive study of the British workforce funded ... , The research finds that while British employers have ... competitive market pressures, they have devised ways of extracting ...
... Inc. (Nasdaq: ADLS ), a biopharmaceutical company ... drugs in the,therapeutic areas of infection, cancer and ... of approximately 10.2 million,shares of common stock together ... common stock to a group of new and ...
Cached Medicine News:Health News:Study Shows MammaPrint(R) Breast Cancer Test Provides Benefits to Patients from Personalized Treatment Regimen 2Health News:Study Shows MammaPrint(R) Breast Cancer Test Provides Benefits to Patients from Personalized Treatment Regimen 3Health News:UCR researcher awarded $2.1M stem cell grant to study Alzheimer's disease 2Health News:UCR researcher awarded $2.1M stem cell grant to study Alzheimer's disease 3Health News:Heavy traffic makes breathing a burden in children 2Health News:The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities 2Health News:Workplace opportunities and stresses are both increasing 2Health News:Workplace opportunities and stresses are both increasing 3Health News:Workplace opportunities and stresses are both increasing 4Health News:Advanced Life Sciences Completes Private Placement for $20 Million 2Health News:Advanced Life Sciences Completes Private Placement for $20 Million 3
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 8, 2011 Elsevier, world-leading provider of ... pleased to announce Dr. Steven Schachter, Editor-in-Chief of Elsevier,s ... the prestigious Ambassador for Epilepsy Award by the International ... Epilepsy (ILAE) at the 29 th International ...
... 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... of novel therapeutics targeting cancer metabolism, announced today the ... Company,s lead drug candidate ME-143 in patients with refractory ... with the Sarah Cannon Research Institute in Nashville, Tennessee, ...
Cached Medicine Technology:Editor-in-Chief of Elsevier's Epilepsy & Behavior presented with Ambassador for Epilepsy Award 2Editor-in-Chief of Elsevier's Epilepsy & Behavior presented with Ambassador for Epilepsy Award 3Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3
... The Deluxe specimen bath mounts inside the ... bath allows for the separation of buffer and ... The bath can be sterilized and has round ... mounting specimens. The disks and bath surface ...
... A simple device designed to mount ... This product facilitates the mounting of all ... It is especially useful for mounting tissue ... as those produced with a Vibratome, freezing ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Inquire...
Medicine Products: